Regulus Therapeutics
RGLS
#7008
Rank
โ‚น52.56 B
Marketcap
โ‚น759.21
Share price
0.00%
Change (1 day)
480.61%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚น4.02 Billion

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚น4.3 Billion a decrease over its 2023 earnings that were of -โ‚น2.74 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น4.02 Billion-6.67%
2024 -โ‚น4.3 Billion56.97%
2023 -โ‚น2.74 Billion6.51%
2022 -โ‚น2.58 Billion2.53%
2021 -โ‚น2.51 Billion93.59%
2020 -โ‚น1.3 Billion-15.41%
2019 -โ‚น1.54 Billion-64.46%
2018 -โ‚น4.31 Billion-33.26%
2017 -โ‚น6.46 Billion-13.98%
2016 -โ‚น7.51 Billion44.77%
2015 -โ‚น5.19 Billion-1.63%
2014 -โ‚น5.27 Billion203.6%
2013 -โ‚น1.74 Billion8.65%
2012 -โ‚น1.6 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚น716.34 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚น144.81 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น867.87 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น1.312 T-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น920.70 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚น10.15 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚น10.95 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น53.57 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA